Find out how Google DeepMind's AlphaFold3 platform could help scientists revolutionize the field of drug discovery.

Since Abcam's acquisition in 2023, founder Jonathan Milner has been making waves with his investment strategy. Discover his ...

After years of setbacks, biotechs are advancing treatments for Huntington’s disease, offering new hope as clinical studies ...

The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.